Beta Thalassemia B Thal Epidemiology Forecast

DelveInsight’s ‘Beta-thalassemia – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Beta-thalassemia epidemiology in the 6MM, i.e., the United States and EU5 (Germany, Spain, Italy, France, and the United Kingdom).

Geographies Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Study Period: 2017–2030

Radiation-induced Esophagitis: Understanding

The DelveInsight’s Beta-thalassemia epidemiology report gives a thorough understanding of Beta-thalassemia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Beta-thalassemia in the US and Europe. Moreover, the report covers the detailed information of the Beta-thalassemia epidemiology scenario in six major countries (US and EU5).

Epidemiology Perspective by DelveInsight

This section encompassing Beta-thalassemia epidemiology provides insights about historical and current patient pool and forecasted trend for every six major countries. The RIE epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 6MM. This segment covers the epidemiology data in the US and EU5 countries (Germany, Spain, Italy, France, and the UK), from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Detailed Epidemiology Segmentation

The Beta-thalassemia epidemiology covered in the report provides historical as well as forecasted RIE epidemiology scenario in the 6MM covering the United States and EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and from 2017 to 2030.

The report also provides the epidemiology trends observed in the 6MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Beta-thalassemia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Beta-thalassemia report and model provide an overview of the global trends of RIE in the seven major markets (6MM: US, France, Germany, Italy, Spain, and the UK).
  • The report provides insight into the historical and forecasted patient pool of Beta-thalassemia in six major markets covering the United States and EU5 (Germany, Spain, France, Italy and the UK).
  • The report helps to recognize the growth opportunities in the 6MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Beta-thalassemia.
  • The report provides the segmentation of the Beta-thalassemia epidemiology

Report Highlights:

  • 11-year Forecast of Beta-thalassemia Epidemiology
  • 6MM Coverage
  • Total prevalent cases of Beta-thalassemia minor
  • Diagnosed prevalence of Beta-thalassemia
  • Diagnosed Beta-thalassemia patients by disease type
  • Complications associated with Beta-thalassemia patients

KOL Views

We interview KOLs and include SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 6MM concerning the patient population pertaining to Beta-thalassemia?
  • What are the key findings pertaining to the Beta-thalassemia epidemiology across 6MM and which country will have the highest number of patients during the forecast period (2017–2030)?
  • What would be the total number of patients of Beta-thalassemia across the 6MM during the forecast period (2017–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
  • At what CAGR the patient population is expected to grow in 6MM during the forecast period (2017–2030)?
  • What is the disease risk, burden and unmet needs of Beta-thalassemia?
  • What are the currently available treatments of Beta-thalassemia?

Reasons to buy

The Beta-thalassemia Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global Beta-thalassemia market.
  • Quantify patient populations in the global Beta-thalassemia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Beta-thalassemia (RIE) therapeutics in each of the markets covered
  • Understand the magnitude of Beta-thalassemia population by its epidemiology
  • The Beta-thalassemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation

• Disease Risk & Burden

• Risk of disease by the segmentation

• Factors driving growth in a specific patient population

1 Key Insights

2 Executive Summary of Beta Thalassemia

3 SWOT Analysis for Beta Thalassemia

4 Beta Thalassemia Market Overview at a Glance

4.1 Market Share (%) Distribution of Beta-thalassemia in 2017

4.2 Market Share (%) Distribution of Beta-thalassemia in 2030

5 Disease Background and Overview

5.1 Introduction

5.2 Types

5.3 Molecular Genetics

5.4 Causes and Risk Factors

5.5 Complications associated with Beta-thalassemia

5.6 Etiology

5.7 Symptoms

5.8 Pathophysiology

5.9 Clinical Presentation of Beta-thalassemia

5.10 Diagnosis

5.11 Newborn Screening in Beta-thalassemia

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 6MM Total Prevalent Patient Population of Beta-thalassemia

6.3 Assumptions and Rationale – 6MM

7 Country Wise-Epidemiology of Beta Thalassemia

7.1 The United States

7.1.1 Total Prevalent Cases of Beta-thalassemia Minor in the United States

7.1.2 Diagnosed Prevalence of Beta-thalassemia in the United States

7.1.3 Diagnosed Beta-thalassemia Patients by Disease Type in the United States

7.1.4 Complications Associated with Beta-thalassemia Patients in The United States

7.2 EU5 Countries

7.2.1 Germany

7.2.1.1 Total Prevalent Cases of Beta-thalassemia Minor in Germany

7.2.1.2 Diagnosed Prevalence of Beta-thalassemia in Germany

7.2.1.3 Diagnosed Beta-thalassemia Patients by Disease Type in Germany

7.2.1.4 Complications Associated with Beta-thalassemia Patients in Germany

7.2.2 France

7.2.2.1 Total Prevalent Cases of Beta-thalassemia Minor in France

7.2.2.2 Diagnosed Prevalence of Beta-thalassemia in France

7.2.2.3 Diagnosed Beta-thalassemia Patients by Disease Type in France

7.2.2.4 Complications Associated with Beta-thalassemia Patients in France

7.2.3 Italy

7.2.3.1 Total Prevalent Cases of Beta-thalassemia Minor in Italy

7.2.3.2 Diagnosed Prevalence of Beta-thalassemia in Italy

7.2.3.3 Diagnosed Beta-thalassemia Patients by Disease Type in Italy

7.2.3.4 Complications Associated with Beta-thalassemia Patients in Italy

7.2.4 Spain

7.2.4.1 Total Prevalent Cases of Beta-thalassemia Minor in Spain

7.2.4.2 Diagnosed Prevalence of Beta-thalassemia in Spain

7.2.4.3 Diagnosed Beta-thalassemia Patients by Disease Type in Spain

7.2.4.4 Complications Associated with Beta-thalassemia Patients in Spain

7.2.5 The UK

7.2.5.1 Total Prevalent Cases of Beta-thalassemia Minor in the UK

7.2.5.2 Diagnosed Prevalence of Beta-thalassemia in the UK

7.2.5.3 Diagnosed Beta-thalassemia Patients by Disease Type in the UK

7.2.5.4 Complications associated with Beta-thalassemia Patients in the UK

8 Treatment and Management of Beta Thalassemia

8.1 Transfusion Therapy

8.2 Guidelines

8.3 Patient Journey

8.4 Organizations contributing towards Beta-thalassemia

9 Case Study

9.1 Acquired Beta-thalassemia as an Etiology of Microcytic Anemia in Primary Myelofibrosis

9.2 Beta-thalassemia Presenting as an Acute Neurological Complication: A Case Report

10 Unmet Needs

11 Appendix

11.1 Report Methodology

12 DelveInsight Capabilities

13 Disclaimer

14 About DelveInsight


Tables of Contents

Table 1: Summary of Beta-thalassemia Market, Epidemiology, and Key Events (2017–2030)

Table 2: Difference between Beta-thalassemia major and intermediate based on different parameters:

Table 3: Prevalent Patient Population of  Beta-thalassemia in 6MM (2017–2030)

Table 4: Total Prevalent Cases Beta-thalassemia Minor in the United States (2017–2030)

Table 5: Diagnosed Prevalence of Beta-thalassemia in the United States (2017–2030)

Table 6: Diagnosed Beta-thalassemia Patients by Disease Type in the United States (2017–2030)

Table 7: Complications associated with Beta-thalassemia Patients in the United States (2017–2030)

Table 8: Total Prevalent Cases Beta-thalassemia Minor in Germany (2017–2030)

Table 9: Diagnosed Prevalence of Beta-thalassemia in Germany (2017–2030)

Table 10: Diagnosed Beta-thalassemia Patients by Disease Type in Germany (2017–2030)

Table 11: Complications associated with Beta-thalassemia Patients in Germany (2017–2030)

Table 12: Total Prevalent Cases Beta-thalassemia Minor in France (2017–2030)

Table 13: Diagnosed Prevalence of Beta-thalassemia in France (2017–2030)

Table 14: Diagnosed Beta-thalassemia Patients by Disease Type in France (2017–2030)

Table 15: Complications associated with Beta-thalassemia Patients in France (2017–2030)

Table 16: Total Prevalent Cases Beta-thalassemia Minor in Italy (2017–2030)

Table 17: Diagnosed Prevalence of Beta-thalassemia in Italy (2017–2030)

Table 18: Diagnosed Beta-thalassemia Patients by Disease Type in Italy (2017–2030)

Table 19: Complications associated with Beta-thalassemia Patients in Italy (2017–2030)

Table 20: Total Prevalent Cases Beta-thalassemia Minor in Spain (2017–2030)

Table 21: Diagnosed Prevalence of Beta-thalassemia in Spain (2017–2030)

Table 22: Diagnosed Beta-thalassemia Patients by Disease Type in Spain (2017–2030)

Table 23: Complications associated with Beta-thalassemia Patients in Spain (2017–2030)

Table 24: Total Prevalent Cases Beta-thalassemia Minor in the United Kingdom (2017–2030)

Table 25: Diagnosed Prevalence of Beta-thalassemia in the United Kingdom (2017–2030)

Table 26: Diagnosed Beta-thalassemia Patients by Disease Type in the United Kingdom (2017–2030)

Table 27: Complications associated with Beta-thalassemia Patients in the United Kingdom (2017–2030)

List of Figures

Figure 1: SWOT Analysis

Figure 2: Chromosome 11

Figure 3: Red blood cells: healthy and affected

Figure 4: Classification of Beta-thalassemia by types:

Figure 5: Inheritance pattern of Beta-thalassemia

Figure 6: Possible complications associated with Beta-thalassemia

Figure 7: Symptoms of Beta-thalassemia

Figure 8: Pathophysiology of Beta-thalassemia

Figure 9: Clinical and Psychosocial concerns among the patients in different age-groups

Figure 10: Diagnostic algorithm of Beta-thalassemia

Figure 11: Prevalent Patient Population of Beta-thalassemia in 6MM (2017–2030)

Figure 12: Total Prevalent Cases of Beta-thalassemia Minor in the United States (2017–2030)

Figure 13: Diagnosed Prevalence of Beta-thalassemia in the United States (2017–2030)

Figure 14: Diagnosed Beta-thalassemia Patients by Disease Type in the United States (2017–2030)

Figure 15: Complications associated with Beta-thalassemia Patients in the United States (2017–2030)

Figure 16: Total Prevalent Cases of Beta-thalassemia Minor in Germany (2017–2030)

Figure 17: Diagnosed Prevalence of Beta-thalassemia in Germany (2017–2030)

Figure 18: Diagnosed Beta-thalassemia Patients by Disease Type in Germany (2017–2030)

Figure 19: Complications associated with Beta-thalassemia Patients in Germany (2017–2030)

Figure 20: Total Prevalent Cases of Beta-thalassemia Minor in France (2017–2030)

Figure 21: Diagnosed Prevalence of Beta-thalassemia in France (2017–2030)

Figure 22: Diagnosed Beta-thalassemia Patients by Disease Type in France (2017–2030)

Figure 23: Complications associated with Beta-thalassemia Patients in France (2017–2030)

Figure 24: Total Prevalent Cases of Beta-thalassemia Minor in Italy (2017–2030)

Figure 25: Diagnosed Prevalence of Beta-thalassemia in Italy (2017–2030)

Figure 26: Diagnosed Beta-thalassemia Patients by Disease Type in Italy (2017–2030)

Figure 27. Complications associated with Beta-thalassemia Patients in Italy (2017–2030)

Figure 28: Total Prevalent Cases of Beta-thalassemia Minor in Spain (2017–2030)

Figure 29: Diagnosed Prevalence of Beta-thalassemia in Spain (2017–2030)

Figure 30: Diagnosed Beta-thalassemia Patients by Disease Type in Spain (2017–2030)

Figure 31: Complications associated with Beta-thalassemia Patients in Spain (2017–2030)

Figure 32: Total Prevalent Cases of Beta-thalassemia Minor in the UK (2017–2030)

Figure 33: Diagnosed Prevalence of Beta-thalassemia in the UK (2017–2030)

Figure 34: Diagnosed Beta-thalassemia Patients by Disease Type in the UK (2017–2030)

Figure 35: Complications associated with Beta-thalassemia Patients in the UK (2017–2030)

Figure 37: Overview of current management of Beta-thalassemia

Figure 38: Beta-thalassemia and its severity based on transfusion dependency

Figure 39: Patient journey for Beta-thalassemia

Figure 40: Unmet Needs of Beta-thalassemia

Figure 54: Market Drivers for Beta-thalassemia

Figure 55: Market Barriers for Beta-thalassemia

  • Tags:
  • Beta-thalassemia (B-thal) Epidemiol...
  • Beta-thalassemia (B-thal)
  • Beta-thalassemia (B-thal) Pipeline
  • Beta-thalassemia (B-thal) Companie...
  • Beta-thalassemia (B-thal) prevalen...
  • Beta-thalassemia (B-thal) incident...
  • Beta-thalassemia (B-thal) patients...
  • Beta-thalassemia (B-thal) treatmen...

Forward to Friend

Need A Quote